## Regularly Scheduled Series OU DERMATOLOGY GRAND ROUNDS/MORPHOLOGY CONFERENCE

Course No. 21D18

Thursday, May 13, 2021 7:45 – 8:45 a.m.

Title: "Psoriasis: Diagnosis and Optimizing Treatment Selection"

Presented by:

Elizabeth F. Prater, MD, FAAD



**Professional Practice Gap**: (1) Some dermatologists have limited knowledge on how to select the best treatment for a patient with psoriasis and lupus. (2) Some dermatologists have limited knowledge of how to select the best treatment for a patient with psoriasis and hepatitis. (3) Some dermatologists have limited knowledge on how to select the best treatment for a patient with psoriasis and Crohn's Disease.

**Learning Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

- 1. Learn tips and pearls for how to efficiently and correctly identify patients with psoriasis.
- 2. Identify and review literature sources that can help select the right psoriasis treatments for each patient.
- 3. Apply the knowledge above to real life cases.

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit $^{\text{TM}}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Conflict Resolution Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, <a href="mailto:bjm@ou.edu">bjm@ou.edu</a>, or visit <a href="https://www.ou.edu/eoo.">www.ou.edu/eoo.</a>.

**Accommodation Statement:** For accommodations, please contact Shana Levin at 405-271-6110 and/or email at <a href="mailto:shana-levin@ouhsc.edu">shana-levin@ouhsc.edu</a>.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Faculty and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also discloses discussions of unlabeled/ unapproved uses of drugs or devices during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

## **Disclosure & Resolution Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity's disclosure information.

			Nature of Relevant Financial Relationship		
Role	First Name	Last Name	Commercial interest	What was received?	For what role?
Case Presenter / Moderator	Pamela S.	Allen, MD	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Case Presenter / Moderator	Lindsey K.	Collins, MD	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Case Presenter / Moderator	Jason M.	Hirshburg, MD	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Case Presenter / Moderator	Allison N.	Hood, MD	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Planning Committee / Moderator	Jarad I.	Levin, MD	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Course Contact	Shana R.	Levin	I have no relevant finan interests to disclose.	cial relationships or affili	ations with commercial
Presenter	Elizabeth F.	Prater, MD, FAAD	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Course Director / Moderator / Presenter	Thomas	Stasko, MD	Pfizer, Inc.	Contracted Research	Site principle investigator for investigational drug in atopic dermatitis

**Organizer:** The conflict was resolved by Dr. Stasko agreeing to recuse himself from planning content in the conflicted area. **Moderator:** The conflict was resolved by Dr. Stasko agreeing to limit his role to the introductions of presenters, fielding questions and moderating the flow of discussion between participants and presenters. **Presenter:** The conflict was resolved by Dr. Stasko agreeing to refrain from making recommendations on topics in which the conflicts exists and agreeing that the presentation will not include discussion of any product or services from the listed commercial interest.

Planning Committee	Matthew P.	Stephany, MD	I have no relevant financial relationships or affiliations with commercial
			interests to disclose.